WO1999025330A1

WO1999025330A1 - Treatment of scar tissue using lipoic acid

Info

Publication number: WO1999025330A1
Application number: PCT/US1998/024514
Authority: WO
Inventors: Nicholas V. Perricone
Original assignee: Perricone Nicholas V
Priority date: 1997-11-17
Filing date: 1998-11-16
Publication date: 1999-05-27
Also published as: CA2309717A1; DE69831269T2; DE69831269D1; HK1030155A1; ES2247728T3; CA2309717C; JP2001522878A; EP1039891A4; JP4027593B2; EP1039891B1; EP1039891A1; ATE301996T1; US5965618A

Abstract

Scar tissue is reduced or inhibited by application of a composition containing lipoic acid and/or a lipoic acid derivative such as dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures of any of these. Some compositions further comprise α-hydroxy acids or acid derivatives such as glycolic and/or lactic acid, fatty acid esters of ascorbic acid such as ascorbyl palmitate, and/or tocotrienol. In some embodiments, a silicone gel sheet with added lipoic acid and/or a lipoic acid derivative and optional other ingredients is topically applied to scar tissue to diminish them.

Description

TREATMENT OF SCAR TISSUE USING LIPOIC ACID

Technical Field

This invention relates primarily to methods and compositions for the treatment of scar tissue, particularly hypertrophic and keloid scars and straie distensae (stretch marks). Scars typically result from repair of damaged tissue, and this damage may be following trauma, burns, or disease. Because scars are cosmetically distracting and sometimes symptomatic, producing bothersome itching, burning, stinging or painful sensations, there is considerable interest in their treatment.

Background of the Invention

Scars result from wound healing, which occurs in three separate phases: inflammation, formation of granulation tissue, and matrix formation. (For a review, see Sahl, W.J., and Clever, H., Internat. J. Derm., 1994, 33: 681-691 (part I) and 763-769 (part II)). During the first phase, damage to endotiielial cells, complement, and platelets at the wound site release chemotactic factors that result in the infusion of neutrophils, lymphocytes and macrophages, which aids in the removal of infection and foreign debris. As in all inflammatory processes, there is generation of free radicals, which damages cell membranes and results in formation of oxidized proteins and fats, and cross-linked new collagen, laying a scaffold for the next phase. At the end of the inflammatory phase, the granulation phase begins with an influx of fibroblasts and endothelial cells to the wound. Other key cells in this phase are macrophages and platelets. Macrophages induce the beginning of granulation by relasing platelet-derived growth factor (PDGF), tumor necrosis growth factor (TGF)-α, and an epidermal growth factor-like substance. Activated platelets release epidermal growth factor (EGF), PDGF, TGF-α, and TGF-3. Together these play roles in the re-epithelialization process wherein keratinocytes cells migrate in sheaths over a provisional matrix consisting primarily of fibrin, fibronectin, type V collagen, and tenascin, and produce their own fibronectin receptors.

Once re-epithelilization has occurred, keratinocytes resume their normal differentiated form, and matrix formation begins. Matrix formation consists primarily of the construction of derma matrix, which is regulated by fibroblasts. Chemotaxis of fibroblasts results in the production of abundant quantities of hyaluronate, fibronectin, and types I and III collagen. These components comprise the bulk of the provisional extracellular matrix in the early part of this wound repair phase. Hyaluronic acid (HA) creates an open- weave pattern in the colla- gen/fibronectin scaffold, facilitating fibroblast movement. HA production falls after about the fifth day of wound healing, and levels of chronroitin sulfate in dermatan sulfate increase. Fibronectin deposits in me collagen, and wound contraction begins. Biochemically during the contraction stage, hyaluronidase and proteinase are present, type I collagen synthesis is stimulated, and increased levels of chronroitin sulfate, dermatin sulfate and proteoglycans are observed; together these restructure the matrix. At the end of the healing process, the final scar shows collagen fibers mostly parallel to the epidermis.

Hypertrophic and keloid-type scars result in extension of scar tissue so that a bulky lesion results. A keloid is an exuberant scar that proliferates beyond the original wound. It should be noted that keloids only occur in humans, often causing burning, stinging and itching sensations as well as cosmetic embarrass- ment. The etiology of unsightly keloid formation is not known. However, in keloids, fibronectin formation continues for years, while fibronectin formation in normal scars disappears within a few days after wound closure. Keloid scars exhibit a high rate of collage synthesis in comparison to normal scars, and a low proportion of cross-linked collagen.

Hypertrophic scars sometimes are difficult to distinguish from keloid scars histologically and biochemically, but unlike keloids, hypertropic scars remain confined to the injury site and often mature and flatten out over time. Both types secrete larger amounts of collagen than normal scars, but typically the hypertro- phic type exhibits declining collagen synthesis after about six months. However, hypertrophic scars contain nearly twice as much glycosaminoglycan as normal scars, and this and enhanced synthetic and enzymatic activity result in significant alterations in the matrix which affects the mechanical properties of the scars, including decreased extensibility that makes them feel firm.

Atrophic scars are characterized by a thinning and diminished elasticity

* of the skin due to a loss of normal skin architecture. An example of an atrophic scar is striae distensae, also known as stretch marks. Striae commonly occur in postpartum women after childbirth and also during times of larger-than-average weight gain and also in association with steroids. Atrophic scars are sometimes also observed after trauma, infection and disease, and may show loss of surface markings and smoothness or dry, fine wrinkles over time.

Formation of scars, especially hypertrophoic and keloid scars, is dependent on systemic growth factors such as interleukins and other cytokines, and their influence on fibronectin and collagen biosynthesis. Cytokines are released and are present in die wound healing process and sometimes are released in the inflammatory stage. Growth factors and odier cytokines vary in the inflammatory stage and are released based, among other complex interactions, upon the redox state of the cells. The presence of free radicals in me inflammatory stage plays an important factor in wound healing. Factors that increase the presence of free radicals, such as infection, radiation, and continued trauma, may instigate hypertrophic and keloid scar formation. It is important to note mat cytokines have been suggested to regulate nitric oxide synthetase, which controls the formation of nitric oxide, which plays an important role in signal transduction in the cells. It has also been suggested that nitric oxide synthetase activity is aberrant in keloid scars when compared to normal scar tissue (Lim, T.C., et al, Plastic and Reconst. Surgery, 1996, 95:911-912). Hypertrophic and keloid scars also show inflammatory activity that is not seen in mature scars.

Many scar treatments have been suggested, but few are satisfactory. Treatment of keloid or hypertrophic scars have consisted of surgical excision followed in many cases by graft application. Pressure has also been used to cause scar thinning after injury or scarring. For example, pressure bandages placed over scars have resulted in some scar diinning, but a pressure of at least about 25 mm Hg must be maintained constantly for approximately six mondis in usual situations for any visually observable effect. Ionizing radiation merapy has also been employed. Otfier treatments include application of silicone pads to the scar tissue surface, sometimes under pressure provided by an elastomeric bandage, applica- tion of silicone gel sheets, witii or without added vitamin E (Palmieri, B., et al, J. Derm., 1995, 34: 506-509), and topical or intralesional treatment with cortico- steroids.

Scars are one of die strongest forces driving the cosmetic industry. It would be desirable to have alternative, preferably new and improved, treatments for scar reduction and remodeling. Summary of the Invention

It is an objective of this invention to provide compositions and methods for the treatment and inhibition of scar tissue, including hypertrophic, keloid, and atrophic scars.

It is another and more specific objective of me invention to provide topical compositions and memods for scar reduction and inhibition based upon topical application of compositions containing lipoic acid and/or lipoic acid derivatives, typically in association with a dermatologically acceptable carrier or vehicle and/or a silicone gel sheet, to scars and to injured skin sites susceptible to scarring.

These and odier objectives are accomplished by me present invention, which provides compositions and memods for me treatment and/or inhibition of cutaneous scars, which comprises topical application to the scars or injured skin areas of an effective amount of lipoic acid, lipoic acid derivatives or mixtures mereof. Some embodiments employ compositions containing lipoic acid and/or a lipoic acid derivative in a dermatologically acceptable carrier which is applied to diminish or inhibit scar tissue. Others utilize a silicone gel sheet having added lipoic acid and/or a lipoic acid derivative which is applied to scar tissue.

Ascorbic acid, particularly fat-soluble fatty acid esters of ascorbic acid such as ascorbyl palmitate, can, optionally, also be utilized for further enhancing the efficacy of me therapeutic or prophylactic treatment. In other embodiments, tocotrienols or derivatives mereof or vitamin E compositions enriched with toco- trienols or tocotrienol derivatives such as tocotrienol-enriched fractions of natural oils are included in die lipoic acid composition wim or without an ascorbic acid ingredient. Still odier embodiments include α-hydroxy acids or their derivatives and the like in the lipoic acid composition wiύ or without other optional ingredients. In a preferred practice of the invention, the lipoic acid (or derivative) is applied in admixture with a dermatologically acceptable carrier or vehicle (e.g. , as a lotion, cream, ointment, soap, or the like) so as to facilitate topical application and, in some cases, provide additional therapeutic effects as might be brought about, e.g., by moisturizing of the affected skin areas. As noted, other ingredients, particularly ascorbyl palmitate and/or tocotrienol and/or an α-hydroxy acid, can be advantageously included in die compositions. In one preferred embodiment, a silicone gel sheet having added lipoic acid and/or dihydrolipoic acid and/or other optional ingredients is applied to scar tissue or injured cutaneous sites susceptible to scarring.

The amount of lipoic acid or derivative mereof (hereinafter referred to collectively as lipoic acid or LA for ease of reference) necessary to bring about enhanced reduction and/or inhibition of scar tissue is not fixed per se, and necessarily is dependent upon the identity and form of lipoic acid employed, the amount and type of any additional ingredients (such as ascorbyl esters, tocotrienol, and/or α-hydroxy acids) used, die user's skin type, and d e severity and extent of die patient's scarring. In some typical embodiments, me composition contains from about 0.1 % to about 7 weight %, lipoic acid or dihydrolipoic acid. In one embodiment, about 2% to 3% lipoic acid is employed.

Detailed Description of the Invention

This invention is based upon die finding mat lipoic acid and/or its derivatives are useful for me reduction and inhibition of epidermal and subepider- mal cutaneous scar tissue, including underlying membrane and connective tissue typically damaged in various types of skin trauma.

As used herein, die term "lipoic acid" encompasses thioctic acid (1,2- didιiolane-3-pentanoic acid; l,2-didιiolane-3-valeric acid), C₈H₁₄O₂S₂, formula weight 206.32. Lipoic acid was originally identified as a bacterial growth factor present in d e water-soluble fraction of liver and yeast. It was found to be necessary for d e oxidative decarboxylation of pyruvic acid by Streptococcus fecalis and for the grow i of Tetraftymena gelii, and replaced acetate for die growth of Lactobacillus casei. It has been variously known as acetate replacing factor, protogen A, and pyruvate oxidation factor.

Subsequent research showed diat lipoic acid (LA) was a growth factor for many bacteria and protozoa, and it served as a prosmetic group, coenzyme, or substrate in plants, microorganisms, and animal tissues. Elucidation of its struc- ture and function determined d at it is a co-factor for α-keto-dehydrogenase complexes, typically bound as lipoamide, that participates in acyl transfer reactions. Its reduced form, dihydrolipoic acid, is a potent sulfhydryl reductant. In aqueous systems, bom exhibit antioxidant actions. Some experiments have shown that lipoic acid may maintain microsomal protein iols, protect against hemolysis, and protect against neurological disorders (mentioned in me introduction of

Maitra, et al, Free Rod. Biol. Med. 1995, 75:823-829). The protective effect of dietary supplementation of LA against ischemia/reperfusion injury in me Langen- dorff isolated heart model has also been suggested (ibid.). LA has been used in treating liver cirrhosis, atheroschlerosis, and polyneuritis of diabetes mellitus (ibid.). Results of ex vivo rat experiments using butathione sulfoximine suggested LA might be useful in preventing cataracts (ibid.), and die compound was disclosed as an ingredient witfi odiers for tyrosinase inhibition in a cosmetic composition for skin whitening (Abstract, Jap. Ap. Pub. 63008315). It has also been used as an antidote to poisonous mushrooms (particularly Amanita species, Merck Index, 11th ed., 1989, entry 9255).

Lipoic acid derivatives include iioctic acid esters, particularly alkyl esters such as fatty acid esters, amides, particularly those isolated from or mimicking naturally occurring lipoamides, salts, particularly alkali metal salts, anhydrides and specifically includes die reduced form, dihydrolipoic acid and its esters, amides and salts. Since lipoic acid is both fat- and water-soluble, it is an advantage of the invention d at it can be used in eid er lipid- or aqueous-based compositions, and it readily crosses cellular membranes and disperses in extracellular and intracellular tissue components. Derivatives may also include iose involving other reactive groups known to mose skilled in d e art. As used herein, the term "derivatives" includes metabolic precursors of lipoic acid. Where lipoic acid derivatives are employed, diey must be functionally equivalent to lipoic acid.

As mentioned above, lipoic acid is fat-soluble. Therefore, lipoic acid preparations can be applied neat to scar tissue. It is an advantage of die invention that die active compound is fatty so mat it physically contributes to die lubrication of affected skin areas to which it is applied.

However, only effective amounts of lipoic acid are needed to reduce or inhibit scar tissue, so generally topical application to exposed or affected skin sites is accomplished in association widi a carrier, and particularly one in which the active ingredient is soluble er se or is effectively solubilized (e.g., as an emulsion or microemulsion) or available when applied in a silicone gel sheet or other linament. Where employed, die carrier is inert in die sense of not bringing about a deactivation of die lipoic acid or derivative, and in die sense of not bringing about any adverse effect on die skin areas to which it is applied.

Suitable carriers include water, alcohols, oils and die like, chosen for their ability to dissolve or disperse lipoic acid and any od er ingredients used in the treatment. Generally, even low concenu-ations of active ingredients in a carrier are suitable, depending upon me application regimen and adjunct ingredients employed. Many embodiments contain from about 0.1 % to about 7% by weight LA or LA derivative. Many embodiments contain more man 1 weight % lipoic acid and/or lipoic acid derivative, e.g., from about 1.1% to about 3 to 5 weight % LA. One efficacious embodiment contains from about 2% to about 3 % by weight. Examples are illustrated hereafter. While the carrier for lipoic acid can consist of a relatively simple solvent or dispersant, it is generally preferred that the carrier comprise a composition more conducive to topical application, and particularly one which will form a film or layer on the skin to which it is applied so as to localize the application and provide some resistance to perspiration and/or one which aids in percutaneous delivery and penetration of die active ingredients into lipid layers of the scarred area. Many such compositions are known in the art, and can take die form of lotions, creams, gels or even solid compositions (e.g., stick-form preparations). Typical compositions include lotions containing water and/or alcohols and emol- lients such as hydrocarbon oils and waxes, silicone oils, hyaluronic acid, vegetable, animal or marine fats or oils, glyceride derivatives, fatty acids or fatty acid esters or alcohols or alcohol ed ers, lanolin and derivatives, polyhydric alcohols or esters, wax esters, sterols, phospholipids and die like, and generally also emul- sifiers (nonionic, cationic or anionic), altiiough some of the emollients inherently possess emulsifying properties. These same general ingredients can be formulated into a cream rather dian a lotion, or into gels, or into solid sticks by utilization of different proportions of die ingredients and/or by inclusion of diickening agents such as gums or other forms of hydrophillic colloids. Such compositions are referred to herein as dermatologically acceptable carriers. Most preferred for skin are those carriers which are fat-soluble, i.e., diose which can effectively penetrate skin layers and deliver LA to all skin layers.

Alternative embodiments employ a silicone gel sheet or other linament to which LA and/or an LA derivative has been added. These may be pressure or adhesive bandages. Silicone gel sheets useful in die practice of the invention are typically cross-linked polydimethylsiloxane containing or impregnated witfi LA and/or an LA derivative. It is an advantage of die invention diat LA augments e effectiveness of previously disclosed methods of using silicone pads or gel sheets for dimim^hing scars (see Palmieri, et al, cited above). As summarized above, many preferred embodiments of this invention contain at least one odier ingredient in addition to lipoic acid. For example, fat-soluble fatty acid esters of ascorbic acid (vitamin C) may be added to the lipoic acid composition in some embodiments. The more oxidation-resistant saturated fatty acid esters of ascorbic acid are preferred, including, but not limited to, ascorbyl laurate, ascorbyl myristate, ascorbyl palmitate, ascorbyl stearate, and ascorbyl behenate. Ascorbyl palmitate is used in one embodiment. As denoted herein, where fatty acid esters are described, e.g., ascorbyl stearate, compositions having predominantly mat ester, e.g., predominandy stearate, are included. The esters may be prepared using hydrogenated oils or fats, or fractions diereof, and contain small amounts of anomer ester. Ascorbyl stearate prepared using canola, for example, commonly contain about 4% ascorbyl palmitate.

α-Hydroxy acids and/or dieir derivatives may also be added to lipoic acid compositions of die invention witii or widiout added ascorbyl esters. As used herein, die terminology "α-hydroxy acid" has reference to and encompasses me general class of organic compounds containing at least one hydroxy group and at least one carboxyl group, and wherein at least one hydroxyl group is located on the α-carbon atom. Typically, me compounds are organic acids having at least one carboxylic acid group and at least one hydroxyl group on die α-carbon atom, and may contain other functional groups including additional hydroxyl and carboxylic acid moieties. Most typically, α-hydroxy acids will have a basic structure of lower aliphatic compounds having from two to six carbon atoms.

The "derivatives" of diese α-hydroxy acids most typically will involve derivatives related to me carboxyl functionality, i.e., wherein die hydrogen or hydroxyl portion of the carboxyl moiety is substituted by metallic ions (to form salts), alkoxy groupings (to form esters), ammonium ions (to form ammonium salts), as well as other substitution reactions and products leading to formation of corresponding lactones, anhydrides or amines. However, the derivatives may also include reactions involving the α-hydroxyl group, most notably ketone formation, to form corresponding α-keto carboxylic acids.

Among the hydroxy acids and derivative compounds useful in the present invention are hydroxy monocarboxylic acids such as glycolic acid, hy- droxymediylglycolic acid, lactic acid, glucuronic acid, galacturonic acid, gluconic acid, glucoheptonic acid, α-hydroxybutyric acid, α-hydroxyisobutyric acid, α-hydroxyvaleric acid, α-hydroxyisovaleric acid, α-hydroxycaproic acid, and α-isocaproic acid. Also included are di- and tri-carboxylic hydroxy acids such as tartronic acid, tartaric acid, malic acid, hydroxyglutaric acid, hydroxyadipic acid, hydroxypimelic acid, muric acid, citric acid, isocitric acid, saccharic acid, dihydroxymaleic acid, dihydroxytartaric acid, and dihydroxyfumaric acid. Derivatives involving keto groups include keto acids and keto esters such as pyruvic acid, methyl pyrivate, ethyl pyruvate, isopropyl pyruvate, benzoylformic acid, memyl benzoylformate, and ed yl benzoylformate. In some preferred embodi- ments, α-hydroxy acids having an aliphatic backbone of 2 to 3 carbons such as glycolic and/or lactic acid or meir derivatives are employed.

Tocotrienol may also be added to lipoic acid compositions of the invention, alone or in combination wid an ascorbyl esters and/or α-hydroxy acids or their derivatives in some embodiments. The term "tocotrienol" encompasses natural and/or syn etic counterparts of tocopherol (vitamin E) that bear unsatu- rated tails, and include, but not limited to, α-, β-, γ-, and δ-tocotrienols, tocotrienol P25, desmethyl-tocotrienol, didesmethyl-tocotrienol, eir syndietic counterparts, their counterparts having methylated or demediylated chroman rings, and mixtures thereof. The double bonds may be cis or trans or mixtures thereof.

Tocotrienol useful in compositions of me invention may be tocotri- enol-enriched vitamin E preparations obtained from natural or syn ietic sources, such as ose obtained by removal of tocopherol from vitamin E compositions. Many embodiments employ tocotrineol isolated from natural sources such as tocotrienol-enriched fractions obtained from sunflower seed, wheat germ, bran, palm, or other vegetable oils by high performance liquid chromatography or other methods, or tocotrienol-enriched extracts obtained from barley, brewer's grains oats, and otiier tocotrienol-containing natural products by alcohol extraction, molecular distillation and d e like. Useful tocotrienols can be tocotrienol-enriched fractions or extracts, or mixtures of these witii vitamin E fractions. As used herein, die term "tocotrienols" includes all of diese tocotrienol-rich fractions and extracts obtained from these natural products as well as die pure compounds and mixtures of any of tiiese.

As witii otiier vitamin E preparations, tocotrienol or tocotrienol-enriched preparations include diose containing tocotrienol and, in some cases, tocopherol derivatives, particularly stabilized derivatives. These typically include derivatives related to the phenolic hydroxyl functionality, i.e., wherein it is acylated with an organic acid to form an ester. Examples of such stabilized tocotrienols include, but are not limited to, tocotrienol acetate, tocotrienol succinate, and mixtures thereof. However, the derivatives may also include diose involving other reactive groups known to tiiose skilled in the art. Where tocotrienol derivatives are employed, tiiey must be functionally equivalent to tocotrienol. Preferred derivatives contain both the chromanol nucleus and tiiree double bonds in the hydrocar- bon tail.

While not wishing to be bound to any tiieory, it is possible diat lipoic acid is efficacious in die treatment of scar tissue because it is fat- and water- soluble and readily disperses in cell membranes and otiier cellular components. It acts as a free radical scavenger and neutiralizer, and prevents die cross-linking of cell membranes that is seen in scar formation, particularly keloid scar formation. By the same token, LA modulation of free radicals and otiier oxidative species affects gene expression, including expression of nuclear factor κ-B (NF-κB), nitric oxide syntiietase and otiier mediators at all stages of proinflammation and inflammation. Lipoic acid's alteration of lipid peroxidation, protein cross-linking, growth factor stimulation, and membrane permability may explain its negative effect on scar tissue formation.

The method of die present invention is particularly useful for reducing or inhibiting scars caused by minor lacerations, surgical wounds, vaccines, burns, and abrasions, as well as stretch marks observed in aging and after weight loss or childbirth and various types of fibroses. Generally, die composition is topically applied to d e affected skin areas in a predetermined or as-needed regimen either at intervals by application of a lotion or the like, or continuously using a silicone gel sheet, it generally being the case that gradual improvement is noted witii each successive application. Insofar as has been determined based upon clinical studies to date, no adverse side effects are encountered.

The following examples are presented to further illustrate and explain the present invention and should not be taken as limiting in any regard. Unless odierwise indicated, all percentages are by weight.

Examples

Fifteen patients between the ages of 20 and 57 years who had hypertrophic scars applied a composition containing 5 % glycolic acid and 1 % α-lipoic acid in a lecithin base to the scars twice daily for a period of tiiree montiis. The scars were observed and photographed at weeks 4, 8, and 12. Comparison of me assessment photographs with those taken of unttreated lesions showed a greater than 50% reduction in lesions in 90% of e patients.

A second study was made on five subjects aged 18 to 30 years having striae distensae. Compositions containing 3% lipoic acid, a 1 % tocotrienol-rich palm oil fraction, and 1 % ascorbyl palmitate were applied to die striae twice daily for two months. At the end of that period, two of the subjects exhibited an 80% reduction in striae, while die remainder showed a 50% reduction in striae.

The papers and patents cited above are expressly incorporated in their entireties by reference.

The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all diose obvious modifications and variations of it which will become apparent to die skilled worker upon reading die description. It is intended, however, that all such obvious modifications and variations be included witiiin the scope of the present invention, which is defined by d e following claims. The claims are intended to cover d e claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.

Claims

1. A topical composition for me treatment or inhibition of cutaneous scar tissue comprising a lipoic acid ingredient and an ╬▒-hydroxy acid ingredient.

2. A composition according to claim 1 wherein the lipoic acid ingredient is at least one compound selected from the group consisting of lipoic acid, dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures thereof.

3. A composition according to claim 2 wherein me lipoic acid ingredient is lipoic acid, dihydrolipoic acid, or mixtures thereof.

4. A composition according to claim 1 wherein the ╬▒-hydroxy acid ingredient is a compound having an aliphatic backbone of 2 to 3 carbons selected from the group consisting of a free acid, an acid salt, an anhydride, a fatty acid ester, and mixtures tiiereof.

5. A composition according to claim 4 wherein the ╬▒-hydroxy acid ingredient is selected from the group consisting of glycolic acid, lactic acid, and mixtures mereof.

6. A composition according to claim 1 comprising from about 0.1% to about 7% lipoic acid ingredient.

7. A composition according to claim 1 comprising a combination of lipoic acid and glycolic acid.

8. A composition according to claim 1 further comprising a tocotrienol.

9. A composition according to claim 8 wherein me tocotrienol is selected from the group consisting of ╬▒-tocotrienol, ╬▓-tocotrienol, 7-tocotrienol, ╬┤-tocotrienol, desmethyl-tocotrienol, didesmethyl-tocotrienol, tocotrienol-P25 , and mixtures thereof.

10. A composition according to claim 8 which comprises a tocotrienol-rich fraction of a natural oil.

11. A silicone gel sheet impregnated witii the composition of claim 1.

12. A topical composition for the treatment or inhibition of cutaneous scar tissue comprising lipoic acid or a lipoic acid derivative and a fatty acid ester of ascorbic acid.

13. A composition according to claim 12 wherein d e lipoic acid derivative is selected from the group consisting of dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures ereof.

14. A composition according to claim 12 comprising from about 0.1 % to about 7% lipoic acid or lipoic acid derivative.

15. A composition according to claim 12 wherein the fatty acid ester of ascorbic acid is selected from the group consisting of ascorbyl palmitate, ascorbyl laurate, ascorbyl myristate, ascorbyl stearate, and mixtures thereof.

16. A composition according to claim 12 comprising lipoic acid and ascorbyl palmitate.

17. A composition according to claim 12 further comprising a tocotrienol.

18. A composition according to claim 17 wherein the tocotrienol is selected from the group consisting of ╬▒-tocotrienol, jS-tocotrienol, ╬│-tocotrienol, ╬┤-tocotrienol, desmethyl-tocotrienol, didesmethyl-tocotrienol, tocotrienol-P25 and mixtures thereof.

19. A composition according to claim 17 which comprises a tocotrienol-rich fraction of a natural oil.

20. A silicone gel sheet impregnated with the composition of claim 12.

21. A topical composition for the treatment or inhibition of cutaneous scar tissue comprising, as an active ingredient, greater tiian 1 % lipoic acid or a lipoic acid derivative in a dermatologically acceptable carrier.

22. A composition according to claim 21 wherein the lipoic acid derivative is selected from the group consisting of dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures thereof.

23. A composition according to claim 21 wherein the composition comprises lipoic acid, dihydrolipoic acid, or mixtures thereof.

24. A composition according to claim 21 wherein the composition comprises from about 1.1% to about 7% lipoic acid or a lipoic acid derivative.

25. A composition according to claim 21 further comprising a tocouienol.

26. A composition according to claim 25 wherein the tocotrienol is selected from the group consisting of ╬▒-tocotrienol, jS-tocotrienol, ╬│-tocotrienol, ╬┤-tocotrienol, desmethyl-tocotrienol, didesmethyl-tocotrienol, tocotrienol P-25 and mixtures thereof.

27. A composition according to claim 25 which comprises a tocotrienol-rich fraction of a natural oil.

28. A silicone gel sheet having added lipoic acid or a lipoic acid derivative.

29. A sheet according to claim 28 wherein the lipoic acid derivative is selected from the group consisting of dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures tiiereof.

30. A method for the u-eatment or inhibition of cutaneous scar tissue comprising applying to said tissue a composition containing lipoic acid or a lipoic acid derivative in a dermatologically acceptable carrier.

31. A metiiod according to claim 30 wherein the lipoic acid derivative is selected from me group consisting of dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures thereof.

32. A method according to claim 30 wherein the composition comprises lipoic acid, dihydrolipoic acid, or mixtures tiiereof.

33. A method according to claim 30 wherein the composition comprises from about 0.1 % to about 7% lipoic acid or lipoic acid derivative.

34. A method according to claim 30 wherein the composition further comprises an ╬▒-hydroxy acid or an ╬▒-hydroxy acid derivative.

35. A method according to claim 34 wherein the composition comprises glycolic acid.

36. A method according to claim 30 wherein the composition further comprises a fatty acid ester of ascorbic acid.

37. A metiiod according to claim 36 wherein the fatty acid ester of ascorbic acid is ascorbyl palmitate.

38. A method according to claim 30 wherein the composition further comprises a tocotrienol.

39. A method according to claim 30 for the treatment of scar tissue.

40. A method according to claim 39 wherein silicone gel sheets impregnated witii the composition are applied to die scar tissue.